|Awarded On||February 16, 2022|
|Title||Signaling network modeling to identify new treatments for triple-negative breast cancer|
|Award Mechanism||Individual Investigator Research Awards for Computational Biology|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Bing Zhang|
Triple-negative breast cancer (TNBC) is a deadly disease accounting for 15-20% of the annual new cases of invasive breast cancer in the U.S. Genomic characterization of TNBC has not identified therapeutically targetable, high-frequency "driver" alterations, which has impeded development of molecularly targeted therapies. Most TNBC patients are treated with cytotoxic chemotherapy regimens with only marginal success. Kinases are frequently dysregulated in human cancer and are attractive targets for therapeutic intervention. Recent advancements in mass spectrometry (MS)-based proteomics allow unbiased characterization of proteins and their modifications in clinical tumor specimens, providing ne...